Exact Mass: 367.1737

N-Allylsecoboldine

C22H25NO4 (367.1783)

Prucalopride

C18H26ClN3O3 (367.1663)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D005765 - Gastrointestinal Agents > D054368 - Laxatives Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3].

Pyrazoloacridine

C19H21N5O3 (367.1644)

C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D007364 - Intercalating Agents D000970 - Antineoplastic Agents

4-[[1-(4-Tert-Butylphenyl)-5-oxo-3-pyrrolidinyl]methoxy]benzoic acid

C22H25NO4 (367.1783)

Knightolamine

C22H25NO4 (367.1783)

N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1h-indole-3-carboxamide

C21H22FN3O2 (367.1696)

6-benzoyloxy-2-(hydroxy-phenyl-methyl)-8-methyl-nortropan-3-ol

C22H25NO4 (367.1783)

Q63399172

C22H25NO4 (367.1783)

marmesiline|N-[2-hydroxy-2-[4-[(2-hydroxy-3-methyl-3-butenyl)oxy]phenyl]ethyl]-3-phenyl-(2E)-2-propenamide

C22H25NO4 (367.1783)

daphnicyclidin A

C22H25NO4 (367.1783)

Val Tyr Ser

C17H25N3O6 (367.1743)

Thr Thr Phe

C17H25N3O6 (367.1743)

Val Ser Tyr

C17H25N3O6 (367.1743)

Thr Phe Thr

C17H25N3O6 (367.1743)

Ser Val Tyr

C17H25N3O6 (367.1743)

Tyr Val Ser

C17H25N3O6 (367.1743)

Phe Thr Thr

C17H25N3O6 (367.1743)

SCHEMBL3193422

C17H25N3O6 (367.1743)

Ser Tyr Val

C17H25N3O6 (367.1743)

1,2,9,10-tetramethoxy-6,7-dimethyl-5,6-dihydro-4H-dibenzo[de,g]quinoline

C22H25NO4 (367.1783)

relative retention time with respect to 9-anthracene Carboxylic Acid is 1.137 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.143

Tyr Ser Val

C17H25N3O6 (367.1743)

Lys-Leu-OH

C17H25N3O6 (367.1743)

Lys-Ile-OH

C17H25N3O6 (367.1743)

Leu-Lys-OH

C17H25N3O6 (367.1743)

Ile-Lys-OH

C17H25N3O6 (367.1743)

Fmoc-7-Ahp-OH

C22H25NO4 (367.1783)

Dimoxyline

C22H25NO4 (367.1783)

C78281 - Agent Affecting Musculoskeletal System > C29696 - Muscle Relaxant

3-(3-N-BOC-AMINO-PYRROLIDIN-1-YL)-1-(6-CHLORO-PYRIDIN-3-YL)-2-METHYL-PROPAN-1-ONE

C18H26ClN3O3 (367.1663)

1-(6-CHLORO-PYRIDIN-3-YL)-2-METHYL-3-(4-BOC-PIPERAZIN-1-YL)-PROPAN-1-ONE

C18H26ClN3O3 (367.1663)

1-(6-CHLORO-PYRIDIN-3-YL)-3-(4-BOC-PIPERAZIN-1-YL)-BUTAN-1-ONE

C18H26ClN3O3 (367.1663)

Fmoc-N-Me-Leu-OH

C22H25NO4 (367.1783)

5-(4-(Methylsulfonyl)piperazin-1-yl)pyridine-3-boronic acid pinacol ester

C16H26BN3O4S (367.1737)

benzyl(triphenyl)phosphanium,boranuide

C25H25BP (367.1787)

Fmoc-β-Homo-Leu-OH

C22H25NO4 (367.1783)

3-[benzyl(propan-2-yl)amino]-1-naphthalen-2-ylpropan-1-one,hydrochloride

C23H26ClNO (367.1703)

Fmoc-Neopentylglycine

C22H25NO4 (367.1783)

Fmoc-N-Me-Ile-OH

C22H25NO4 (367.1783)

Fmoc-N-Methyl-D-leucine

C22H25NO4 (367.1783)

Pramiracetam sulfate

C14H29N3O6S (367.1777)

C26170 - Protective Agent > C1509 - Neuroprotective Agent

(R)-N-FMoc-α-Methylleucine

C22H25NO4 (367.1783)

Fmoc-HomoLeu-OH

C22H25NO4 (367.1783)

(S)-N,N-DIMETHYL-8,9,10,11,12,13,14,15-OCTAHYDRODINAPHTHO[2,1-D:1,2-F][1,3,2]DIOXAPHOSPHEPIN-4-AMINE

C22H26NO2P (367.1701)

ZM 39923 HCl

C23H26ClNO (367.1703)

Fmoc-β-homoisoleucine

C22H25NO4 (367.1783)

Pitofenone

C22H25NO4 (367.1783)

C78272 - Agent Affecting Nervous System > C29698 - Antispasmodic Agent

3-(9H-fluoren-9-ylmethoxycarbonylamino)heptanoic acid

C22H25NO4 (367.1783)

N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-2-methyl-L-leucine

C22H25NO4 (367.1783)

Benzoicacid, 2-[4-(cyclohexylethylamino)-2-hydroxybenzoyl]-

C22H25NO4 (367.1783)

Fmoc-D-Homoleucine

C22H25NO4 (367.1783)

Tyroservaltide

C17H25N3O6 (367.1743)

1-[4-(Aminomethyl)benzoyl]-5-fluoro-1H-spiro[piperidine-4,2-quinazolin]-4-amine

C20H22FN5O (367.1808)

prucalopride

C18H26ClN3O3 (367.1663)

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation C78272 - Agent Affecting Nervous System > C47794 - Serotonin Agonist D005765 - Gastrointestinal Agents > D054368 - Laxatives Prucalopride is an orally active, selective and specific 5-HT 4 receptor agonist (high affinity), with pKis of 8.6 and 8.1 for human 5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer[1][2][3].

(3E)-3-[(2E,4E,6E)-1-hydroxy-8-methyldeca-2,4,6-trienylidene]-5-[(4-hydroxyphenyl)methyl]pyrrolidine-2,4-dione

C22H25NO4 (367.1783)

5-(3-Methylbenzylidene)-2-[(1,7,7-trimethylbicyclo[2.2.1]hept-2-ylidene)hydrazono]-1,3-thiazolidin-4-one

C21H25N3OS (367.1718)

7-(diethylamino)-N-[(4-fluorophenyl)methyl]-2-imino-1-benzopyran-3-carboxamide

C21H22FN3O2 (367.1696)

3-[(4-Ethoxycarbonyl-4-phenyl-1-piperidinyl)methyl]benzoic acid

C22H25NO4 (367.1783)

N-[5-ethyl-1-(2-morpholin-4-ylethyl)-2-oxo-3H-indol-3-yl]acetamide;hydrochloride

C18H26ClN3O3 (367.1663)

[1-(2,1,3-Benzothiadiazol-5-ylmethyl)-4-(2-phenylethyl)-4-piperidinyl]methanol

C21H25N3OS (367.1718)

(2S,3S,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

Val-Tyr-Ser

C17H25N3O6 (367.1743)

(2S,3S,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2S,3S,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2S,3S,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-ylazetidine-1-carboxamide

C21H22FN3O2 (367.1696)

(2S,3R,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-ylazetidine-1-carboxamide

C21H22FN3O2 (367.1696)

(2R,3S,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3R,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3R,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2S,3R,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2S,3R,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3S,4R)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3S,4S)-2-cyano-3-[4-(2-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propyl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3R,4S)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3R,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2S,3R,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

(2R,3S,4R)-2-cyano-3-[4-(4-fluorophenyl)phenyl]-4-(hydroxymethyl)-N-propan-2-yl-1-azetidinecarboxamide

C21H22FN3O2 (367.1696)

N-hydroxy-N-[(E)-(4-hydroxy-2,6-dimethoxyphenyl)methylideneamino]octanediamide

C17H25N3O6 (367.1743)

Rilpivirine(1+)

C22H19N6+ (367.1671)

Thr-Phe-Thr

C17H25N3O6 (367.1743)

Val-Ser-Tyr

C17H25N3O6 (367.1743)

Ser-Val-Tyr

C17H25N3O6 (367.1743)

Phe-Thr-Thr

C17H25N3O6 (367.1743)

Ser-Tyr-Val

C17H25N3O6 (367.1743)

Thr-Thr-Phe

C17H25N3O6 (367.1743)

Tyr-Val-Ser

C17H25N3O6 (367.1743)

Tyr-Ser-Val

C17H25N3O6 (367.1743)

(2e)-n-[(2r)-2-hydroxy-2-(4-{[(2s)-2-hydroxy-3-methylbut-3-en-1-yl]oxy}phenyl)ethyl]-3-phenylprop-2-enimidic acid

C22H25NO4 (367.1783)

n-[(2r)-2-hydroxy-2-(4-{[(2s)-2-hydroxy-3-methylbut-3-en-1-yl]oxy}phenyl)ethyl]-3-phenylprop-2-enimidic acid

C22H25NO4 (367.1783)

7-hydroxy-2-[hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate

C22H25NO4 (367.1783)

(1s,2r,3s,5s,7r)-7-hydroxy-2-[(s)-hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate

C22H25NO4 (367.1783)

(1r,2r,3r,5r,7s)-7-hydroxy-2-[(r)-hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-3-yl benzoate

C22H25NO4 (367.1783)

3-hydroxy-2-[hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate

C22H25NO4 (367.1783)

(12s,16s,17r,19r,20s)-22-hydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

C22H25NO4 (367.1783)

(1s,2r,3r,5s,6s)-3-hydroxy-2-[(s)-hydroxy(phenyl)methyl]-8-methyl-8-azabicyclo[3.2.1]octan-6-yl benzoate

C22H25NO4 (367.1783)

22-hydroxy-16,20-dimethyl-4-oxa-14-azahexacyclo[15.4.1.0²,⁷.0⁸,²¹.0¹²,²⁰.0¹⁴,¹⁹]docosa-1(22),2(7),8(21)-triene-3,9-dione

C22H25NO4 (367.1783)

4,5,15,16-tetramethoxy-8,10-dimethyl-10-azatetracyclo[7.7.1.0²,⁷.0¹³,¹⁷]heptadeca-1(17),2(7),3,5,8,13,15-heptaene

C22H25NO4 (367.1783)